Jubilant Ingrevia Ltd Q4 FY26 Earnings Call: Guides ≥20% EBITDA Growth for FY27, Specialty Margin Sustained Above 27%

Jubilant Ingrevia Ltd held its Q4 FY26 earnings call on May 26, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financial Performance

• Rs.1,179 crore— Q4 FY 2025-2026 revenue, the highest in 14 quarters, driven by 10% volume growth and 12% YoY expansion.
• Rs.172 crore— Q4 FY26 EBITDA, also the highest in 14 quarters, up 11% YoY and 26% QoQ; operating margin of 14.6%.
• Rs.86 crore— Q4 FY26 PAT, up 17% YoY and 84% QoQ, reflecting strong operational leverage and improved working capital.
• 0.99x— Net debt-to-EBITDA ratio at Q4 FY26 close, improved from prior periods.
• Rs.79.8 crore— Total cash outflow for FY26 dividend of Rs.5 per share (500%), including a final dividend of Rs.2.5 per share (250%) recommended by the Board.

Specialty, Nutrition & Chemical Intermediates

• Rs.516 crore— Specialty Chemicals achieved its best-ever quarterly revenue in Q4 FY26; full-year FY26 revenue was Rs.1,937 crore (up 7% YoY) with EBITDA of Rs.510 crore (up 21% YoY).
• 27%+— Specialty Chemicals segment EBITDA margin sustained above this level for six consecutive quarters through Q4 FY26; post corporate overheads the margin landed at ~25%, within the guided 23-25% range.
• Rs.230 crore— Nutrition business revenue in Q4 FY26, up 21% YoY and 15% QoQ, with segment EBITDA of Rs.32 crore (margin 14%); full-year FY26 revenue was Rs.790 crore and EBITDA Rs.100 crore.
• Rs.433 crore— Chemical Intermediates revenue in Q4 FY26, up 15% YoY and 10% QoQ, supported by strong domestic agrochemical and paracetamol demand; management expects recovery aided by European force majeure and plant closures.
• Acquisition of Remidex— Forward-integration into human nutrition premixes, leveraging existing customer relationships and Vitamin B3 / B4 molecules.

Growth Engine & Molecule Pipeline

• 20-plus confirmed molecules— Under the Pinnacle strategy, with 10-plus advanced-stage molecules representing aggregate peak potential of Rs.1,100 crore; 100-plus opportunities valued at ~Rs.3,500 crore.
• 30-40%— Annual CDMO revenue growth rate in FY26; management expects growth to accelerate in FY27, with the $300 million agro contract (signed October FY25, commercial deliveries from March FY26) as a key pillar.
• 8 new molecules— Added to the CDMO pipeline in Q4 FY26, bringing the total to over 15 molecules; traction with 5-6 top innovators at the highest-ever level.
• 3x— Pharma CDMO pipeline growth over the last 1.5-2 years with innovators and tier-1 CDMOs; ~70% of the pipeline is non-pyridine-based, leveraging 30-plus chemistries.
• 2 agrochemical molecules— Secured and executed "first time right"; currently 6-8 additional molecules under discussion in agro.
• Rs.120 crore— Lean savings achieved; Bharuch CDMO plant commissioned in 14 months; ranked 97th percentile in S&P Global CSA.

Profitability, Capex & Efficiency

• 23-25%— Sustainable EBITDA margin guidance for the specialty chemical portfolio post corporate overheads (ongoing target); Q4 FY26 reported specialty margin of 26-26.5% adjusts to ~25% after overhead allocation.
• 59 days— Net working capital improvement, down from prior periods.
• Rs.150 crores— Capital work-in-progress remaining after capitalising the CDMO plant in March 2026 (Q4 FY26).
• Rs.400-500 crores— Annual capex guidance for FY 2026-2027, with the major outlay being the Gajraula MPPA plant (expected completion and production start in Q4 FY26-27).
• Rs.500 crores— Capex guided for FY 2027-2028, in line with investor day commitments to invest behind growth.

FY27 Outlook & Medium-Term Targets

• ≥20%— Management targets year-on-year EBITDA growth for FY 2026-2027 (full-year basis); quarterly phasing may vary due to contract timing.
• Sequential growth from Q1 FY27— Management expects revenue and EBITDA to grow sequentially from Q1 FY 2026-2027, led by specialty chemicals and nutrition with recovery in acetates.
• "3× revenue and 4× EBITDA targets by FY30"— Management reiterated confidence in this long-term goal (verbatim from segment 6), supported by 20-25% annual EBITDA growth from FY27 onwards and recent pricing recovery.
• FY27 is a "pivotal year"— Management stated FY 2026-2027 is a pivotal year for acceleration, with growth expected to begin in Q1 FY 2026-2027.
• $300M contract volume— Customer provided volume visibility for Q1 FY 2026-2027 with contractual commitment to make Jubilant Ingrevia whole if any shortfall occurs.
• Acetates recovery— European competitors announced force majeure due to mechanical failures; management expects to gain volumes and market share in Europe during FY 2026-2027 due to prior product qualifications.

Pyridine Market, B3 Plant & Regional Traction

• 90%+— Jubilant Ingrevia's 50,000-tonne pyridine plant utilization in Q4 FY26, versus Chinese plants operating at 30-40% utilization (global pyridine capacity ~2.5-3 lakh tonnes in China, per management).
• "At rock bottom"— Current pyridine pricing per management, while beta picoline is at multi-year highs; historical multi-month average pricing has been $2.5-$3.5/kg.
• ~50% of peak— PC-grade niacinamide volumes at the human-grade B3 plant (ramp started FY 2025-2026); niacin (food/feed) projected to reach 40-50% of peak volumes in FY 2026-2027.
• "Very small"— Semiconductor chemicals revenue currently; over a dozen projects underway with increased opportunities from Japan and international firms seeking Indian partners,though ramp-up is slow due to supply chain sensitivity.
• "Rest of world" growth— Strong traction in Japan, Korea, and Southeast Asia for nutrition and personal care businesses during Q4 FY26.